4 assets in Hepatobiliary Neoplasm

Therapeutic assets addressing Hepatobiliary Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Domvanalimab Hepatobiliary Neoplasm	University of Texas Southwestern Medical Center	P2	CCC (53)
Zimberelimab Hepatobiliary Neoplasm	University of Texas Southwestern Medical Center	P2	CCC (53)
Ceralasertib Hepatobiliary Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
Trastuzumab Deruxtecan Hepatobiliary Neoplasm	National Cancer Institute (NCI)	P1	CC (43)